

Edwards PASCAL Transcatheter Valve Repair System TriCLASP Post-Market Study: 30-Day Outcomes




During the late-breaking trial session, Professor Stephan Baldus reported the 30-day outcomes from the prospective, single-arm, multi-centre TriCLASP post-market clinical follow-up (PMCF) study.

Study design & baseline parameters¹

Study Design: Prospective, single-arm, multicentre study	
Enrolled patients: 74	Female: 58%
NYHA functional class III or IV: 77%	Tricuspid regurgitation (≥ severe)*: 83% ^a
Age, years: 80 ± 6	STS score, MV Repair: 9.0 ± 6.9

Key results



Graphs show paired data.

* Core laboratory: Cardialysis.

^a TR severity for 10 patients was reclassified to moderate or less after core lab adjudication.

^b Wilcoxon signed-rank test.

NYHA, New York Heart Association.

STS, Society for Thoracic Surgeons.


TR: tricuspid regurgitation.

MV: mitral valve.



Edwards

- TR reduction at 30 days:
 - **88% of patients achieving ≥ 1 TR grade reduction**
 - **90% had moderate or less TR**
- 97% freedom from major adverse events
- NYHA class I/II was achieved in 56%, 6MWD improved by 38 m, and KCCQ scores improved by 13 points (all $p < 0.001$ from baseline)



Graphs show paired data. ^aWilcoxon signed-rank test. ^bPaired t-test for mean \pm SD. NYHA, New York Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire; 6MWD, 6-minute walk distance

Conclusion

- The transcatheter PASCAL repair system in a European post-market setting confirms both favourable safety and effectiveness at 30 days in symptomatic patients with severe TR.

See what we're making possible at Edwards.com/PASCAL

TR: tricuspid regurgitation.

¹Baldus S. 30-Day outcomes for transcatheter tricuspid repair: TriCLASP post-market study. LBT EuroPCR2022

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--EU-4360 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com